<?xml version="1.0" encoding="UTF-8"?>
<p>Exclusion criteria included the participants' lack of consent to continue the study; taking antibiotics or nonsteroid anti-inflammatory drugs two weeks before the study; gastroesophageal reflux disease (heartburn, acid regurgitation); drug or alcohol abuse; the presence of gastroesophageal malignancy, chronic digestive diseases, and peptic ulcer disease based on history, physical examination, laboratory tests (e.g., white blood cell count, C reactive protein (CRP) or erythrocyte sedimentation rate (ESR)), and upper endoscopy; liver and kidney dysfunction based on laboratory tests; planned or current pregnancy; the history of a severe allergic reaction to medicinal plants; the history of upper gastrointestinal tract surgery; and serious illnesses like heart failure, diabetes and epilepsy, and previous or current significant psychiatric comorbidity [
 <xref rid="B19" ref-type="bibr">19</xref>â€“
 <xref rid="B24" ref-type="bibr">24</xref>]. Participants were not allowed to receive PPIs, H
 <sub>2</sub>-receptor antagonists, antacids, mucosal protectants, prokinetics, antidepressant drugs, anticholinergic agents, and cholinergic agents one week of study commencement or during the study. Upper endoscopy was used to rule out peptic ulcer and malignancy only if there were alarm features such as burning pain in the epigaster which increases during the night and wakes up the patients, frequent vomiting, loss of appetite, family history of gastrointestinal malignancies, lower gastrointestinal bleeding, odynophagia, dysphagia, unexplained significant weight loss, palpable abdominal mass, lymphadenopathy, jaundice, and age over 45 years [
 <xref rid="B19" ref-type="bibr">19</xref>, 
 <xref rid="B20" ref-type="bibr">20</xref>, 
 <xref rid="B25" ref-type="bibr">25</xref>].
</p>
